MET

MetLife Inc

Add to Watchlist

Advanced Chart

76.560

+1.26(1.673%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

76.890

Open

75.780

VWAP

76.53

Vol

4.01M

Mkt Cap

50.91B

Low

75.620

Amount

306.75M

EV/EBITDA(TTM)

9.56

Total Shares

711.12M

65.63B

EV/OCF(TTM)

4.31

P/S(TTM)

0.71

MetLife, Inc. is a financial services company, providing insurance, annuities, employee benefits and asset management to individual and institutional customers. Its segments include Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA); and MetLife Holdings. Group Benefits segment offers life insurance, dental, group short- and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment insurance, accident and health insurance, and vision, as well as prepaid legal plans and pet insurance. RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products. It operates across EMEA in both developed (Western Europe) and emerging (Central and Eastern Europe, Middle East and Africa) markets.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

18.70B

-0.65%

2.244

+14.51%

19.02B

-3.65%

2.403

+14.95%

18.69B

+6.1%

2.368

+21.43%

Estimates Revision

The market is revising Upward the revenue expectations for MetLife, Inc. (MET) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by -5.67%.

Revenue Estimates for FY2025

Revise Upward

+0.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.45%

In Past 3 Month

Stock Price

Go Down

-5.67%

In Past 3 Month

12 Analyst Rating

25.00% Upside

Wall Street analysts forecast MET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MET is 95.70 USD with a low forecast of 85.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

2 Hold

0 Sell

Strong Buy

25.00% Upside

Current: 76.560

Low

85.00

Averages

95.70

High

110.00

25.00% Upside

Current: 76.560

Low

85.00

Averages

95.70

High

110.00

Keefe Bruyette

Outperform -> NULL

downgrade

$94 -> $92

2025-08-11

New

Reason

Keefe Bruyette

Price Target

$94 -> $92

2025-08-11

New

downgrade

Outperform -> NULL

Reason

Keefe Bruyette lowered the firm's price target on MetLife to $92 from $94 and keeps an Outperform rating on the shares. The firm updated estimates in the life insurance group post the Q2 reports.

Wells Fargo

Overweight

maintain

$97 -> $95

2025-08-10

New

Reason

Wells Fargo

Price Target

$97 -> $95

2025-08-10

New

maintain

Overweight

Reason

Wells Fargo lowered the firm's price target on MetLife to $95 from $97 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q2 report. MetLife's quarter was held back by weak disability and voluntary, the analyst tells investors in a research note.

Morgan Stanley

Bob Huang

Overweight

downgrade

$99 -> $98

2025-07-14

Reason

Morgan Stanley

Bob Huang

Price Target

$99 -> $98

2025-07-14

downgrade

Overweight

Reason

Morgan Stanley analyst Bob Huang lowered the firm's price target on MetLife to $98 from $99 and keeps an Overweight rating on the shares.

Wells Fargo

Overweight

maintain

$94 -> $97

2025-07-10

Reason

Wells Fargo

Price Target

$94 -> $97

2025-07-10

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on MetLife to $97 from $94 and keeps an Overweight rating on the shares ahead of quarterly results. The firm says the focus should be on pricing, loss trend, and reserves for P&C companies, organic and margin for brokers, and sales/VII/capital for life companies.

Barclays

Overweight

maintain

$88 -> $94

2025-07-07

Reason

Barclays

Price Target

$88 -> $94

2025-07-07

maintain

Overweight

Reason

Barclays raised the firm's price target on MetLife to $94 from $88 and keeps an Overweight rating on the shares as part of a Q2 earnings preview for the North America life insurance group. The firm says equity market strength has lifted long-term earnings and results in upward revisions to its 2026-2027 estimates. It recommends exposure to names with equity leverage and capital flexibility. Barclays highlights Jackson Financial (JXN) as a key Overweight.

Piper Sandler

Neutral

downgrade

$63 -> $55

2025-07-03

Reason

Piper Sandler

Price Target

$63 -> $55

2025-07-03

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Brighthouse Financial (BHF) to $55 from $63 and keeps a Neutral rating on the shares. The firm is reducing its EPS estimates in the space driven by continued fee and spread headwinds. This was confirmed by a rather challenging pre-announcement of variable investment income from MetLife (MET) in late June suggesting this swing factor for a large chunk of lifecoland got sequentially worse, which also - in Piper's opinion - pushes out the normalization factor towards 2026.

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for MetLife Inc (MET.N) is 8.03, compared to its 5-year average forward P/E of 8.33. For a more detailed relative valuation and DCF analysis to assess MetLife Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

8.33

Current PE

8.03

Overvalued PE

9.45

Undervalued PE

7.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.72

Undervalued EV/EBITDA

-2.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.72

Current PS

0.66

Overvalued PS

0.80

Undervalued PS

0.64